Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › EXEL

Exelixis

EXEL Lead: Approved 9 Biotech Distilled articles ↓ 23 filings & releases ↓ Cash $305M (Oct 2, 2026) ↓ 9 verdicts ↓ 6 timing quotes ↓
CardiovascularOncology ProteinSmall Molecule

Market cap $17.0B 244.0M shares (10-Q, Oct 19, 2026) × $69.57 close Nov 6, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. XL557 / XB773 IND filing2026XL557 / XB773 IND filing, 2026, notable
  2. STELLAR-304 topline1Q 2027STELLAR-304 topline, 1Q 2027, material
  3. Zanzalintinib FDA approvalMar 3, 2027Zanzalintinib FDA approval, Mar 3, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (23 active programs)

zanzalintinib

Small Molecule Target: TYRO3, AXL, MER, MET, VEGF receptors

Technology platforms

SAFEbody · Adagene

Adagene's SAFEbody technology platform for generating masked monoclonal antibodies for ADC or other innovative biotherapeutic development against Exelixis-nominated oncology targets

SMARTag · Catalent

Catalent's SMARTag site-specific bioconjugation technology platform for development of multiple ADCs for oncology

B-Body · Invenra

Invenra's B-Body technology platform for discovery and development of novel binders and multispecific antibodies for oncology

Discontinued (4)

Capital (as filed)

Cash
$305M cash and cash equivalents · Oct 2, 2026 (10-Q)
Short-term investments
$587M Oct 2, 2026
Long-term investments
$508M Oct 2, 2026
Operating cash flow
$280M quarter Jul 3, 2026 → Oct 2, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.40B cash per the update of Oct 29, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Exelixis, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-30 Buy core Exelixis Inc.(EXEL): Scientific Deep Dive for Zanza and Pipeline Products Cash-printing machine with no dilution risk, a de-risked balance sheet, and a clear catalyst in the Zanza CRC launch that could bridge the 2030/2031 patent cliff.
  2. 2026-02-07 Buy core UPDATE: Exelixis (EXEL) - The Clock Starts Now FDA acceptance of the Zanza NDA with a concrete October 15, 2026 PDUFA date validates the buy thesis and de-risks the timeline.
  3. 2026-02-14 Buy core UPDATE: Exelixis (EXEL) - The Receipts Are In Strong Q4/FY2025 earnings, a new institutional whale (AQR 5.09% stake), and the locked October 2026 PDUFA date all confirm the thesis is playing out as mapped.
  4. 2026-05-06 Buy core UPDATE: Exelixis (EXEL) - Q1 prints another cash-gusher quarter and the Board just stacked another $750M on the buyback pile. Q1 cash generation remains strong, a new $750M buyback authorization compounds the float-shrink thesis, and the PDUFA slip to December 3 is a routine adjustment that does not impair the bridge strategy.
  5. 2026-06-22 Buy core UPDATE: Exelixis (EXEL) - STELLAR-303 Clears the Second Bar STELLAR-303 no-liver-mets subgroup reportedly hit statistical significance for OS, retiring meaningful clinical risk on the lead asset and strengthening the CRC launch narrative ahead of the December 3 PDUFA.
  6. 2026-08-06 Speculative buy speculative UPDATE: Exelixis (EXEL) - The Mea Culpa on STELLAR-303 The STELLAR-303 no-liver-mets subgroup actually missed (HR 0.83, P=0.1185) and management trimmed guidance for the first time, weakening the launch narrative; downgrading conviction while the cash floor and ITT approval path remain intact.
  7. 2026-08-31 Buy core UPDATE: Exelixis (EXEL) - The Wolves Get Pushed Back to 2030 CAFC affirmed the CABOMETYX malate salt patents locking January 15, 2030 exclusivity, removing the largest tail risk to the cash engine and satisfying one of the three stated upgrade conditions.
  8. 2026-09-11 Speculative buy speculative UPDATE: Exelixis (EXEL) - The Christmas Present Gets Pushed to Spring FDA issued a major amendment extending the PDUFA to March 3, 2027 after requesting updated safety and efficacy data, adding new uncertainty to a launch narrative already weakened by the NLM miss.
  9. 2026-10-30 Hold UPDATE: Exelixis (EXEL) - The Wolves Found a Side Door Handa received full FDA approval for a cabozantinib capsule via a salt-swap route that bypasses the malate patents, STELLAR-304 slipped to Q1 2027, and the stock is up 18% while the patent picture has weakened — warranting a step down to Hold.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)